A Plethora of GLP-1 Agonists: Decisions About What to Use and When

被引：14

作者：

Samson, Susan L. ^{[1
]}

Garber, Alan J. ^{[2
,3
,4
,5
]}

机构：

[1] Baylor Coll Med, Dept Med, One Baylor Plaza,ABBR R615, Houston, TX 77030 USA

[2] Baylor Coll Med, Dept Med, One Baylor Plaza,BCM 620, Houston, TX 77030 USA

[3] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza,BCM 620, Houston, TX 77030 USA

[4] Baylor Coll Med, Dept Biochem, One Baylor Plaza,BCM 620, Houston, TX 77030 USA

[5] Baylor Coll Med, Dept Mol Biol, One Baylor Plaza,BCM 620, Houston, TX 77030 USA

来源：

CURRENT DIABETES REPORTS | 2016年 / 16卷 / 12期

关键词：

Type; 2; diabetes; Weight loss; Obesity; Impaired glucose tolerance; Impaired fasting glucose; Diabetes prevention; Pre-diabetes; GLUCAGON-LIKE PEPTIDE-1; TYPE-2; DIABETES-MELLITUS; INCRETIN-BASED THERAPIES; ONCE-DAILY LIXISENATIDE; BASAL INSULIN GLARGINE; OPEN-LABEL; RECEPTOR AGONIST; CONTROLLED-TRIAL; EXENATIDE TWICE; CARDIOVASCULAR-DISEASE;

D O I：

10.1007/s11892-016-0823-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Incretin-based therapies are important addition to our armamentarium for the treatment of type 2 diabetes (T2DM). There are six Glucagon-like peptide-1 receptor agonists (GLP-1RAs) which have received regulatory approval for clinical use. The short-acting GLP-1RAs include exenatide twice daily, liraglutide once daily, and lixisenatide once daily. The approved long-acting GLP-1RAs are administered weekly and are exenatide, albiglutide, and dulaglutide. Although all of these therapies lower hemoglobin A1C (HbA1C), there also are unique features of GLP-1RAs that have been made manifest from clinical trial data with regard to weight-loss efficacy, fasting and post-prandial glucose control, cardiovascular safety and protection, and gastrointestinal and injection adverse effects. It is imperative to consider these features when tailoring the choice of a GLP-1RA to patient specific characteristics.

引用

页数：13

共 104 条

[1] Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials [J].

Ahren, B. ;

Gautier, J. -F. ;

Berria, R. ;

Stager, W. ;

Aronson, R. ;

Bailey, C. J. .

DIABETES OBESITY & METABOLISM, 2014, 16 (09) :861-868

[2] Liraglutide: A once-daily human glucagon-like peptide-1 analogue [J].

Aimaretti, G. .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (08) :701-703

[3] 7. Approaches to Glycemic Treatment [J].

不详 .

DIABETES CARE, 2016, 39 :S52-S59

[4]

[Anonymous], 2016, N ENGL J MED

[5] Clinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes [J].

Aroda, Vanita R. ;

DeYoung, Mary Beth .

POSTGRADUATE MEDICINE, 2011, 123 (05) :228-238

[6] A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis [J].

Baggio, LL ;

Huang, QL ;

Brown, TJ ;

Drucker, DJ .

DIABETES, 2004, 53 (09) :2492-2500

[7] A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes [J].

Barrington, P. ;

Chien, J. Y. ;

Showalter, H. D. H. ;

Schneck, K. ;

Cui, S. ;

Tibaldi, F. ;

Ellis, B. ;

Hardy, T. A. .

DIABETES OBESITY & METABOLISM, 2011, 13 (05) :426-433

[8] Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride [J].

Basu, Ananda ;

Charkoudian, Nisha ;

Schrage, William ;

Rizza, Robert A. ;

Basu, Rita ;

Joyner, Michael J. .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2007, 293 (05) :E1289-E1295

[9] THE GLUCAGON SUPERFAMILY - PRECURSOR STRUCTURE AND GENE ORGANIZATION [J].

BELL, GI .

PEPTIDES, 1986, 7 :27-36

[10] Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo [J].

Bentley-Lewis, Rhonda ;

Aguilar, David ;

Riddle, Matthew C. ;

Claggett, Brian ;

Diaz, Rafael ;

Dickstein, Kenneth ;

Gerstein, Hertzel C. ;

Johnston, Peter ;

Kober, Lars V. ;

Lawson, Francesca ;

Lewis, Eldrin F. ;

Maggioni, Aldo P. ;

McMurray, John J. V. ;

Ping, Lin ;

Probstfield, Jeffrey L. ;

Solomon, Scott D. ;

Tardif, Jean-Claude ;

Wu, Yujun ;

Pfeffer, Marc A. .

AMERICAN HEART JOURNAL, 2015, 169 (05) :631-U75

← 1 2 3 4 5 6 7 8 9 10 →